UBS Group’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

UBS Group’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-183	Closed	-$1K	–	11667
2022 Q1	$1K	Sell	183 -922	-83%	-$2.65K	﹤0.01%	10135
2021 Q4	$4K	Buy	1,105 +922	+504%	+$3.43K	﹤0.01%	9627
2021 Q3	$1K	Sell	183 -3,113	-94%	-$16K	﹤0.01%	9424
2021 Q2	$20K	Buy	3,296 +340	+12%	+$2.4K	﹤0.01%	7369
2021 Q1	$36K	Buy	2,956 +6	+0.2%	+$85	﹤0.01%	6867
2020 Q4	$43K	Buy	2,950 +2,302	+355%	+$29.3K	﹤0.01%	6328
2020 Q3	$7K	Buy	+648	New	+$8.31K	﹤0.01%	7167

UBS Group's CMPI Position: Q2 2022 in Review

UBS Group sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 183 shares — an estimated $1K sold.

UBS Group first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $43K in Q4 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

UBS Group reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
UBS Group sold 183 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $1K.
UBS Group first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
UBS Group's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $43K in Q4 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.